"Lactobacillus Rhamnosus L34": A Native Probiotic That Reduces Inflammation in Patients with Chronic Kidney Disease
BANGKOK, April 8, 2026 /PRNewswire/ -- Researchers from the Faculty of Medicine at Chulalongkorn University
{fullname}
About author
You should write because you love the shape of stories and sentences and the creation of different words on a page.
View all posts
Related posts
---
Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology
TOKYO, Oct. 22, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys")
---
NIPRO CORPORATION Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States
New medium-cutoff Dialyzer with a Super High-flux membrane brings NIPRO's approach to expanded hemodialysis
---
Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing
SHANGHAI and YANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or
---
EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may
---
Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy
– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA
---
EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1]
SYDNEY, June 7, 2025 /PRNewswire/ -- New modelling highlights the potential societal, economic and
---
Merry Life Biomedical Advances Global Phase 2 Trial of TML-6, Exploring Cellular Protein Clearance in Early Alzheimer's Disease
Global study brings together nine Taiwan medical centers, seven Swedish sites, and four U.S. centers to
